CHARM-Preserved

Posted by on

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial - The Lancet - 2003

Brief Summary:

In patients with HFpEF and NYHA class II-IV symptoms, the addition of candesartan modestly reduced the rate of HF-related hospitalizations, but had no effect on CV mortality.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/13678871

Comments

Post a Comment

Drop your thoughts here, we would love to hear from you